Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

Impact · against what's priced in

Theravance Biopharma (TBPH) faces negative pressure as a cluster of analyst downgrades to 'Hold' and significant insider selling by major shareholders signal a lack of near-term growth conviction. These bearish signals outweigh the marginal support provided by increased institutional accumulation from Dimensional Fund Advisors and other funds.

TBPH−0.20

No priced-in read yet